News & Updates

Capivasertib, when added to fulvestrant, prolonged progression-free survival (PFS) by 4.1 months in an analysis of Chinese patients with hormone receptor–positive (HR+), HER2-negative (HER2– ABC) advanced breast cancer (ABC) whose disease had progressed on aromatase inhibitor, with or without a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor in the phase III CAPItello-291 trial.